DE60231386D1 - Adenosin-a2a-rezeptor-antagonisten in kombination mit verbindungen mit neurotrophischer aktivität bei der behandlung von morbus parkinson - Google Patents

Adenosin-a2a-rezeptor-antagonisten in kombination mit verbindungen mit neurotrophischer aktivität bei der behandlung von morbus parkinson

Info

Publication number
DE60231386D1
DE60231386D1 DE60231386T DE60231386T DE60231386D1 DE 60231386 D1 DE60231386 D1 DE 60231386D1 DE 60231386 T DE60231386 T DE 60231386T DE 60231386 T DE60231386 T DE 60231386T DE 60231386 D1 DE60231386 D1 DE 60231386D1
Authority
DE
Germany
Prior art keywords
adenosine
treatment
compounds
combination
receptor antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60231386T
Other languages
English (en)
Inventor
Dan Peters
Lars Christian Roenn
Karin Sandager Nielsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NTG Nordic Transport Group AS
Original Assignee
Neurosearch AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch AS filed Critical Neurosearch AS
Application granted granted Critical
Publication of DE60231386D1 publication Critical patent/DE60231386D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
DE60231386T 2001-04-09 2002-04-04 Adenosin-a2a-rezeptor-antagonisten in kombination mit verbindungen mit neurotrophischer aktivität bei der behandlung von morbus parkinson Expired - Lifetime DE60231386D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200100583 2001-04-09
PCT/DK2002/000228 WO2002080957A1 (en) 2001-04-09 2002-04-04 Adenosine a2a receptor antagonists combined with neurotrophic activity compounds in the treatment of parkinson's disease

Publications (1)

Publication Number Publication Date
DE60231386D1 true DE60231386D1 (de) 2009-04-16

Family

ID=8160425

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60231386T Expired - Lifetime DE60231386D1 (de) 2001-04-09 2002-04-04 Adenosin-a2a-rezeptor-antagonisten in kombination mit verbindungen mit neurotrophischer aktivität bei der behandlung von morbus parkinson

Country Status (8)

Country Link
US (1) US7160899B2 (de)
EP (1) EP1379269B1 (de)
JP (1) JP2004529916A (de)
AT (1) ATE424194T1 (de)
CA (1) CA2440196A1 (de)
DE (1) DE60231386D1 (de)
MX (1) MXPA03009185A (de)
WO (1) WO2002080957A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2369746A1 (en) * 1999-05-19 2000-11-30 Neurosearch A/S Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders
EP1361878A1 (de) * 2001-02-15 2003-11-19 Neurosearch A/S Behandlung von morbus parkinson mit der kombinierten wirkung einer verbindung mit neurotroper aktivität und einer verbindung zur verbesserung der dopamin-aktivität
JP4376630B2 (ja) 2002-01-28 2009-12-02 協和発酵キリン株式会社 運動障害治療剤
ES2354875T3 (es) * 2002-12-19 2011-03-18 Schering Corporation Uso de antagonistas del receptor a2a de la adenosina para el tratamiento o prevención del síndrome extrapiramidal.
TW200507850A (en) * 2003-07-25 2005-03-01 Kyowa Hakko Kogyo Kk Pharmaceutical composition
US20070259930A1 (en) * 2006-04-10 2007-11-08 Knopp Neurosciences, Inc. Compositions and methods of using r(+) pramipexole
US8518926B2 (en) * 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
CA2652251A1 (en) 2006-05-16 2007-11-29 Knopp Neurosciences, Inc. Compositions of r(+) and s(-) pramipexole and methods for using the same
US8524695B2 (en) * 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
US8519148B2 (en) * 2007-03-14 2013-08-27 Knopp Neurosciences, Inc. Synthesis of chirally purified substituted benzothiazole diamines
WO2008144931A1 (en) * 2007-05-30 2008-12-04 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels
KR20110071064A (ko) * 2008-08-19 2011-06-28 크놉 뉴로사이언시스 인코포레이티드 (ｒ)-프라미펙솔을 사용하는 조성물 및 방법
TWI548411B (zh) * 2009-04-28 2016-09-11 Kyowa Hakko Kirin Co Ltd Exercise disorder treatment
CA2765876A1 (en) * 2009-06-19 2010-12-23 Knopp Neurosciences, Inc. Compositions and methods for treating amyotrophic lateral sclerosis
US9512096B2 (en) 2011-12-22 2016-12-06 Knopp Biosciences, LLP Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
RS61539B1 (sr) 2013-07-12 2021-04-29 Knopp Biosciences Llc Lečenje povišenih nivoa eozinofila i/ili bazofila
WO2015023786A1 (en) 2013-08-13 2015-02-19 Knopp Biosciences Llc Compositions and methods for treating plasma cell disorders and b-cell prolymphocytic disorders
CA2921381A1 (en) 2013-08-13 2015-02-19 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria
US11413324B2 (en) * 2017-03-17 2022-08-16 University Of Virginia Patent Foundation Compositions and methods for treating peripheral nerve disease, disorders, and injuries
WO2021129843A1 (zh) * 2019-12-26 2021-07-01 浙江春禾医药科技有限公司 三唑并三嗪衍生物在治疗疾病中的用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4325254A1 (de) 1992-08-10 1994-02-17 Boehringer Ingelheim Kg Unsymmetrisch substituierte Xanthine
US5574060A (en) 1993-08-12 1996-11-12 The United States Of America As Represented By The Department Of Health And Human Services Selective inhibitors of biogenic amine transporters
FR2734264B1 (fr) 1995-05-19 1997-08-01 Lafon Labor Utilisation de derives d'alpha-aminomethyl-3,4-dichlorobenzyl-thioacetamide pour la fabrication d'un medicament inhibant la recapture de la dopamine et nouveaux composes pour cette utilisation
US6100275A (en) 1995-10-13 2000-08-08 Neurosearch A/S 8-azabicyclo[3.2.1.]oct-2-ene derivatives, their preparation and use
DE69623799T2 (de) 1995-11-02 2003-01-30 Neurosearch As Ballerup Kondensierte tropanderivate als neurotransmitter-reuptake-inhibitoren
US6180649B1 (en) * 1996-04-19 2001-01-30 Nerosearch A/S 1-(4-piperidyl)-benzimidazoles having neurotrophic activity
US6011070A (en) 1996-08-16 2000-01-04 Allelix-Pharm-Eco L.P. Slow-onset, long-lasting dopamine reuptake blockers
US5821386A (en) 1997-08-15 1998-10-13 Allelix-Pharm-Eco L.P. Compounds for treating cocaine abuse
US6001330A (en) 1997-09-12 1999-12-14 Elmaleh; David R. Diagnostic and therapeutic alkylenediamine compounds and process
WO1999043678A1 (fr) * 1998-02-24 1999-09-02 Kyowa Hakko Kogyo Co., Ltd. Medicaments et prophylaxie contre la maladie de parkinson
WO1999053909A2 (en) 1998-04-23 1999-10-28 Takeda Chemical Industries, Ltd. Pharmaceutical composition for neurotrophic action
CZ20023199A3 (cs) * 2000-02-25 2003-05-14 F. Hoffmann-La Roche Ag Modulátory receptoru adenosinu
US20030104995A1 (en) 2000-04-28 2003-06-05 Reilly Jennifer Ott Neuroprotective methods and compositions

Also Published As

Publication number Publication date
ATE424194T1 (de) 2009-03-15
MXPA03009185A (es) 2004-02-17
CA2440196A1 (en) 2002-10-17
EP1379269A1 (de) 2004-01-14
US7160899B2 (en) 2007-01-09
EP1379269B1 (de) 2009-03-04
US20040097540A1 (en) 2004-05-20
JP2004529916A (ja) 2004-09-30
WO2002080957A1 (en) 2002-10-17

Similar Documents

Publication Publication Date Title
DE60231386D1 (de) Adenosin-a2a-rezeptor-antagonisten in kombination mit verbindungen mit neurotrophischer aktivität bei der behandlung von morbus parkinson
ATE384050T1 (de) Benzazepinderivate als histamin-h3-antagonisten
DK1135153T3 (da) Anvendelser af EPH-receptorantagonister og -agonister til behandling af vaskulære forstyrrelser
NZ522326A (en) Adenosine A2A receptor antagonists
ATE420083T1 (de) Harnstoff-derivate als vanilloid-rezeptor- antagonisten für die schmerzbehandlung
DZ2618A1 (fr) Emploi des antagonistes des récepteurs de 5-HT3 dans le traitement de la colopathie.
PT1054887E (pt) Derivados biciclicos de piridina e pirimidina como antagonistas de receptores no neuropeptido y
ATE293448T1 (de) Benzo(d)azepin-derivative als 5-ht6-rezeptor- antagonisten
EA200601160A1 (ru) 2,6-бисгетероарил-4-аминопиримидины в качестве антагонистов аденозиновых рецепторов
DK1129091T3 (da) Antagonister for CRF-receptorer og fremgangsmåder med relation dertil
TR200102021T2 (tr) TWEAK ve TWEAK reseptörü antagonistleri ve bunların imünolojik bozuklukların iyileştirilmesi için kullanımları
PA8521501A1 (es) Ligandos para receptores de melanocortina
DE602004018637D1 (de) A2a-adenosinrezeptorantagonisten
DK1129096T3 (da) CRF-receptorantagonister og fremgangsmåder, der er relateret dertil
DE50011178D1 (de) Substituierte 1,5-dihydropyrrol-2-on-derivate wirksam als nmda-rezeptor-antagonisten für die behandlung von schmerzzuständen
EA200400399A1 (ru) Способы лечения легочных заболеваний
ATE325117T1 (de) 3,4-dihydrochinolin-2(1h)-on verbindungen als nr2b rezeptor antagonisten
ECSP044971A (es) Isoxazolopiridinonas y su uso en el tratamiento de enfermedad de parkinson
DE60215637D1 (de) Tri- und tetraaza-acenaphthylen-derivate als crf-rezeptor-antagonisten
PT896822E (pt) 4-aminopirrolo (3,2-d)pirimidinas como antagonistas do receptor de neuropeptideo y
DE502004007387D1 (de) Triazolverbindungen und ihre therapeutische verwendung
BR0000486A (pt) Antagonistas do neuropeptìdeo y
DE60102231D1 (de) Crf rezeptor-antagonisten und darauf bezogene methoden
UY26207A1 (es) Antagonistas de los receptores de la il-8.
WO2004067093A3 (en) Nk1 receptor antagonists for the treatment of functional dyspepsia

Legal Events

Date Code Title Description
8364 No opposition during term of opposition